Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Icariin is a naturally occurring flavonoid glycoside isolated primarily from plants of the Epimedium genus, commonly known as Horny Goat Weed. It is a major bioactive constituent in traditional Chinese medicine, used for centuries as an aphrodisiac and for treating erectile dysfunction[1][5]. Icariin acts as a weak phosphodiesterase type 5 (PDE5) inhibitor, enhancing nitric oxide production and cGMP accumulation in smooth muscle cells, which underlies its effects on sexual function[5]. Beyond its use for sexual health, icariin exhibits multiple pharmacological activities including anti-atherosclerotic effects through anti-oxidative, anti-inflammatory, lipid-modulatory actions[3], and has shown potential anticancer properties by inducing apoptosis and inhibiting cell proliferation in various cancer models[6]. Icariin has also been investigated in clinical trials for bipolar disorder and substance abuse disorders. It is widely available over-the-counter globally as a dietary supplement marketed for sexual performance enhancement, athletic performance improvement, memory support, osteoporosis prevention, and other health benefits[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on icariin.